Search clinical trials for: Sevelamer hydrochloride

Total 7438 results

Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

GW786034 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BioCryst Pharmaceuticals

Completed

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Centre Hospitalier Universitaire, Amiens

Terminated

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients (NICOREN)

Hemodialysis | Chronic Renal Failure

France
David P. Richman, MD
Jacobus Pharmaceutical

No longer available

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

Lambert Eaton Myasthenic Syndrome

United States
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
University of Maryland, Baltimore

Suspended

Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride

Aortic Aneurysm, Thoracic

United States
Yizhuo Zhang

Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Sarcoma
Mundipharma K.K.

Completed

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Recurrent or Refractory PTCL

Japan
GlaxoSmithKline

Completed

Post Marketing Surveillance for Contac Bien Z in Japan

Allergic Rhinitis | Seasonal Allergic Rhinitis

Japan
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Non-small Cell Lung Cancer

China
AVEO Pharmaceuticals, Inc.

Completed

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)

Unknown

17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
BioCryst Pharmaceuticals

Completed

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
SK Chemicals Co., Ltd.
Toray Industries, Inc

Completed

Safety Study of TRK-820 for Patient With Hemodialysis (TRK-820)

Chronic Renal Failure

Korea, Republic of
IntraBiotics Pharmaceuticals

Terminated

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

Pneumonia

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
WPD Pharmaceuticals Sp. z o.o.
National Center for Research and Development, Poland; Worldwide Clinical Trials

Terminated

Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

Recurrent Glioblastoma Multiforme

Poland
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China
LanZhou University
General Hospital of Ningxia Medical University

Unknown

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC
Forest Laboratories

Completed

Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia

Dyspepsia
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid Tumours

Neoplasms

China
Gulhane School of Medicine

Completed

Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.

Turkey
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Novel COVID-19-Infected Pneumonia

China
Peking Union Medical College Hospital

Completed

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

Recurrent/Refractory Classical Hodgkin's Lymphoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Myelofibrosis

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Alopecia Areata

China
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Eiger Group International, Inc.

Unknown

Clemizole HCl for Subjects With Hepatocellular Carcinoma

Hepatocellular Carcinoma

Turkey
Forest Laboratories

Completed

Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal

Dyspepsia

Canada
National Institute of Diabetes and Digestive and...

Completed

Regulation of Bone Formation in Renal Osteodystrophy

Secondary Hyperparathyroidism | Renal Osteodystrophy
Boehringer Ingelheim

Completed

Relative Bioavailability of Bromhexine Given as Granules and Syrup in Healthy Volunteers (Clinical Phase I Study)

Healthy

Germany
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Myelofibrosis

China
Yuhong Li

Completed

Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Kubota Vision Inc.

Completed

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Stargardt Disease | Macular Atrophy

United States
Changzhou Cancer Hospital of Soochow University

Unknown

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
Tianjin Anding Hospital

Completed

Berberine Treat Metabolic Syndrome in Schizophrenia

Schizophrenia | Metabolic Syndrome | Female

China
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States
Janssen Research & Development, LLC
Cegedim Strategic Data

Completed

PRILIGY Usage Patterns in Selected Populations

Sexual Dysfunction, Physiological
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Atopic Dermatitis

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China

Search clinical trials for: Sevelamer hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations